Literature DB >> 22648268

An update on the genetics of pheochromocytoma.

D Karasek1, U Shah, Z Frysak, C Stratakis, K Pacak.   

Abstract

Pheochromocytomas (PHEOs) and paragangliomas (PGLs) are rare neuroendocrine tumors. About 30% or more of them are thought to be of inherited origin due to germ-line mutations in at least 10 well-characterized genes. There are data linking specific genotypes of these tumors to specific locations, typical biochemical phenotypes or future clinical behaviors. Conversely, clinical features, catecholamine production and immunohistochemistry evaluation can help with the proper order of genetic testing for PHEO and PGL. The identification of a germ-line mutation can lead to an early diagnosis, appropriate treatment, regular surveillance and better prognosis not only for the patient but also for their family members. Moreover, the latest discoveries in molecular pathogenesis of these tumors will provide an important basis for future personalized therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22648268      PMCID: PMC4060418          DOI: 10.1038/jhh.2012.20

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  59 in total

1.  Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma.

Authors:  Birke Bausch; Wiktor Borozdin; Hartmut P H Neumann
Journal:  N Engl J Med       Date:  2006-06-22       Impact factor: 91.245

Review 2.  Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes?

Authors:  Camilo Jiménez; Gilbert Cote; Andrew Arnold; Robert F Gagel
Journal:  J Clin Endocrinol Metab       Date:  2006-05-30       Impact factor: 5.958

3.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

4.  Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes.

Authors:  Anthony J Gill; Diana E Benn; Angela Chou; Adele Clarkson; Anita Muljono; Goswin Y Meyer-Rochow; Anne Louise Richardson; Stan B Sidhu; Bruce G Robinson; Roderick J Clifton-Bligh
Journal:  Hum Pathol       Date:  2010-03-17       Impact factor: 3.466

5.  Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas.

Authors:  Li Yao; Francesca Schiavi; Alberto Cascon; Yuejuan Qin; Lucia Inglada-Pérez; Elizabeth E King; Rodrigo A Toledo; Tonino Ercolino; Elena Rapizzi; Christopher J Ricketts; Luigi Mori; Mara Giacchè; Antonella Mendola; Elisa Taschin; Francesca Boaretto; Paola Loli; Maurizio Iacobone; Gian-Paolo Rossi; Bernadette Biondi; José Viana Lima-Junior; Claudio E Kater; Marie Bex; Miikka Vikkula; Ashley B Grossman; Stephen B Gruber; Marta Barontini; Alexandre Persu; Maurizio Castellano; Sergio P A Toledo; Eamonn R Maher; Massimo Mannelli; Giuseppe Opocher; Mercedes Robledo; Patricia L M Dahia
Journal:  JAMA       Date:  2010-12-15       Impact factor: 56.272

6.  Germline mutations in TMEM127 confer susceptibility to pheochromocytoma.

Authors:  Yuejuan Qin; Li Yao; Elizabeth E King; Kalyan Buddavarapu; Romina E Lenci; E Sandra Chocron; James D Lechleiter; Meghan Sass; Neil Aronin; Francesca Schiavi; Francesca Boaretto; Giuseppe Opocher; Rodrigo A Toledo; Sergio P A Toledo; Charles Stiles; Ricardo C T Aguiar; Patricia L M Dahia
Journal:  Nat Genet       Date:  2010-02-14       Impact factor: 38.330

Review 7.  Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome.

Authors:  Karel Pacak; Graeme Eisenhofer; Ioannis Ilias
Journal:  Hormones (Athens)       Date:  2009 Apr-Jun       Impact factor: 2.885

8.  c-Myc inhibits Ras-mediated differentiation of pheochromocytoma cells by blocking c-Jun up-regulation.

Authors:  José P Vaqué; Belén Fernández-García; Pablo García-Sanz; Nuria Ferrandiz; Gabriel Bretones; Fernando Calvo; Piero Crespo; María C Marín; Javier León
Journal:  Mol Cancer Res       Date:  2008-02       Impact factor: 5.852

Review 9.  Phaeochromocytomas and sympathetic paragangliomas.

Authors:  B-J Petri; C H J van Eijck; W W de Herder; A Wagner; R R de Krijger
Journal:  Br J Surg       Date:  2009-12       Impact factor: 6.939

10.  Germline SDHB mutations and familial renal cell carcinoma.

Authors:  Christopher Ricketts; Emma R Woodward; Pip Killick; Mark R Morris; Dewi Astuti; Farida Latif; Eamonn R Maher
Journal:  J Natl Cancer Inst       Date:  2008-08-26       Impact factor: 13.506

View more
  19 in total

Review 1.  Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment.

Authors:  Victoria L Martucci; Karel Pacak
Journal:  Curr Probl Cancer       Date:  2014-01-15       Impact factor: 3.187

Review 2.  Neurological Complications of Endocrine Emergencies.

Authors:  Salvador Cruz-Flores
Journal:  Curr Neurol Neurosci Rep       Date:  2021-03-11       Impact factor: 5.081

Review 3.  Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood.

Authors:  Jonathan D Wasserman; Gail E Tomlinson; Harriet Druker; Junne Kamihara; Wendy K Kohlmann; Christian P Kratz; Katherine L Nathanson; Kristian W Pajtler; Andreu Parareda; Surya P Rednam; Lisa J States; Anita Villani; Michael F Walsh; Kristin Zelley; Joshua D Schiffman
Journal:  Clin Cancer Res       Date:  2017-07-01       Impact factor: 12.531

4.  A systematic review on the genetic analysis of paragangliomas: primarily focused on head and neck paragangliomas.

Authors:  A Guha; Z Musil; A Vicha; T Zelinka; K Pacak; J Astl; M Chovanec
Journal:  Neoplasma       Date:  2019-06-29       Impact factor: 2.575

Review 5.  Multiplicity of hormone-secreting tumors: common themes about cause, expression, and management.

Authors:  Stephen J Marx
Journal:  J Clin Endocrinol Metab       Date:  2013-06-14       Impact factor: 5.958

6.  Mutation screening in a Norwegian cohort with pheochromocytoma.

Authors:  Wenche Sjursen; Henrik Halvorsen; Eva Hofsli; Siri Bachke; Asa Berge; Lars F Engebretsen; Sture E Falkmer; Ursula G Falkmer; Jan E Varhaug
Journal:  Fam Cancer       Date:  2013-09       Impact factor: 2.375

7.  EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma.

Authors:  David Taïeb; Henri J Timmers; Elif Hindié; Benjamin A Guillet; Hartmut P Neumann; Martin K Walz; Giuseppe Opocher; Wouter W de Herder; Carsten C Boedeker; Ronald R de Krijger; Arturo Chiti; Adil Al-Nahhas; Karel Pacak; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-28       Impact factor: 9.236

8.  Inhibitory Effect of the Noncamptothecin Topoisomerase I Inhibitor LMP-400 on Female Mice Models and Human Pheochromocytoma Cells.

Authors:  Jan Schovanek; Petra Bullova; Yasin Tayem; Alessio Giubellino; Robert Wesley; Nikoletta Lendvai; Svenja Nölting; Juraj Kopacek; Zdenek Frysak; Yves Pommier; Shivaani Kummar; Karel Pacak
Journal:  Endocrinology       Date:  2015-08-12       Impact factor: 4.736

Review 9.  Familial pheochromocytomas and paragangliomas.

Authors:  Kathryn S King; Karel Pacak
Journal:  Mol Cell Endocrinol       Date:  2013-08-07       Impact factor: 4.102

10.  Surgical Remission of Diabetes in a Patient With Mutation of RET Proto-Oncogene.

Authors:  Marcio José Concepción Zavaleta; Cristian David Armas Flórez; Cesar Joel Benites Moya; Esteban Alberto Plasencia Dueñas; Sofia Pilar Ildefonso Najarro; Kely Palomino Taype; Ricardo Durand Torres; Frederick Massucco Revoredo
Journal:  AACE Clin Case Rep       Date:  2021-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.